SUBSCRIBE
SUBSCRIBE
News   Deals

Vanda Pharmaceuticals, Inc. Sets IPO Price At $12-$14 Per Share

March 21, 2006 | 
1 min read
3/21/2006 – Vanda Pharmaceuticals Inc., which is developing small molecule product candidates for central nervous system disorders, said it has set the terms of its initial public offering of 5.75 million common shares at $12 to $14 per share.
IPO
MORE ON THIS TOPIC
Confrontation and opposite opinions concept. Business people hands pulling rope in opposite directions in office showing power and leadership vector illustration
Mergers & acquisitions
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
March 11, 2026
 · 
5 min read
 · 
Annalee Armstrong
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
March 6, 2026
 · 
1 min read
 · 
Annalee Armstrong
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
 · 
2 min read
 · 
Heather McKenzie
Businessman receiving large stacks of money from a giant hand. Concept of funding, venture capital, financial support, dividend, and profitable business.
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac